Int J Environ Res Publ Health
[11] Any future GLP-1 patch would require robust clinical trial evidence demonstrating efficacy, safety, and pharmacokinetic profiles comparable to existing injectable formulations before regulatory approval could be granted
Published in 1982 the additional sequence appeared to code for a peptide that resembled GIP which in the meantime had been shown to boost glucagon (Lund, Goodman, Dee, Habener
Retatrutide is under clinical development and targets GLP-1, GIP, and glucagon receptors making it a triple agonist
GIPR, unlike the GLP1R, is extensively expressed in the ventricular myocardium of both rodents and humans
Always consult a licensed healthcare provider before starting or changing hormone therapy